Reported Sunday, Celldex Presents Phase 2 Data Showing Up To 64% Of Barzolvolimab-Treated CSU Patients Remained Angioedema-Free Seven Months After Last Dose At EAACI Annual Meeting
Benzinga Newsdesk 4 months ago
News
Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSUSeven months after the completion of dosing (Week 76), up to 64% of patients
- Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU
- Seven months after the completion of dosing (Week 76), up to 64% of patients treated with barzolvolimab who had angioedema at baseline remained angioedema-free
- Barzolvolimab has potential to shift treatment goals from symptom control to disease modification
- Results continue to support ongoing Phase 3 trials of barzolvolimab in CSU; topline data expected in Q4 2026